Filing Flows › Onconetix (ONCO) › Q3 2025
Onconetix (ONCO) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
Onconetix (ONCO) reported revenue of $304K for the third quarter 2025 (Q3 2025), -25% from a year earlier and +185% from the quarter before. Operating margin was -681.5%.
Onconetix, Q3 2025: revenue $304K (-25% year over year), operating margin -681.5%, net loss $8.8M, operating cash flow −$3.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $304K | +185% | -25% |
| Operating profit | −$2.1M | — | — |
| Net earnings | −$8.8M | — | — |
| Operating cash flow | −$3.2M | — | — |
What changed
Revenue was $304K in Q3 2025, down 25% year over year and up 185% from the previous quarter. Other Revenue was the largest line at 98% of revenue.
Gross margin was 88.6%, up 62.6 points from a year earlier. Operating costs exceeded revenue by $2.1M, an operating margin of -681.5%. Operating expenses fell 15% while revenue fell 25%. The quarter ended with a net loss of $8.8M, wider than the previous quarter's $2.4M loss. Net interest and other expense of $6.7M was the main reason.
Operating cash flow was −$3.2M. Non-cash charges added back $3K of depreciation and amortization and $10K of share-based compensation. Working capital and other items added $5.6M.
Questions
What was Onconetix's revenue in the third quarter 2025?
Onconetix (ONCO) reported revenue of $304K for the third quarter 2025 (Q3 2025), -25% from a year earlier and +185% from the quarter before.
Was Onconetix profitable in the third quarter 2025?
Operating loss was $2.1M (-681.5% of revenue) and net loss $8.8M.
Source: Onconetix 10-Q on SEC EDGAR.